The Menopause Digest 05/26 - 06/01

Welcome to The Menopause Digest.

The field moves fast. Too fast for most of us to track every breakthrough, every protocol update, every researcher’s latest findings. That’s where this comes in.

I’ve curated specific shows that consistently deliver evidence-based insights you can actually use. Think less fluff, more substance. The kind of information that changes how you practice or how you live.

Got a podcast that’s been delivering gold? Send it my way. I’m always hunting for voices that push the field forward.

This Newsletter Is Sponsored By Casa de Sante.

Menopause coverage is finally moving from blanket fear to precision prescribing.
That was the through-line in Dr. Shauna Watts’ “The BIGGEST Menopause Misunderstanding of the Last 20 Years,” her later HRT episode, Heather Hirsch’s “Fibroids, Endometriosis, and HRT,” and The DUTCH Podcast: route, timing, and formulation matter more than legacy WHI-era caricatures, with transdermal estradiol generally carrying lower thrombotic burden than oral therapy, low-dose vaginal estrogen usually delivering minimal systemic exposure, and progestogen choice remaining central when the uterus is present or endometriosis risk is in play.
Strategically, that shifts menopause from a “yes/no hormones” debate to a portfolio-management problem—pick the right molecule, the right delivery system, the right monitoring method, and the right duration for the woman in front of you, rather than defaulting to the outdated “lowest dose for the shortest time” reflex.

For anyone on GLP-1 medications like Ozempic or Wegovy, Low FODMAP nutrition is non-negotiable. These medications can slow digestion and trigger bloating or nausea, so choosing gut-friendly products helps you stay comfortable while protecting muscle and metabolism. Physician-formulated by Dr Onyx MD PhD Certified in Obesity Management, this Low FODMAP lineup supports nutrient absorption, muscle defense, and overall digestive balance:

• Premium Protein Powder (Vegan Vanilla, Whey Vanilla, or Whey Chocolate) – helps preserve lean muscle during weight loss

• FODMAP Digestive Enzymes – improves absorption and reduces GI side effects

• Advanced Probiotic + Prebiotic Synbiotic Formula – supports a balanced gut microbiome

• Essential Vitamin & Mineral Complex – replenishes nutrients often depleted during rapid weight loss

• Gentle Colon Cleanse + Probiotic Support – aids regular elimination without irritation

All formulas are low FODMAP, non-GMO, and third-party tested—the ideal foundation for GLP-1 users focused on digestive comfort, metabolic health, and muscle preservation.

Because hormones and skin health are deeply connected, Dr Onyx MD PhD science-backed skincare supports barrier repair, hydration, and inflammation balance for healthy, resilient skin—especially during menopause or while using GLP-1 medications, when collagen loss and dryness can accelerate:

• HydraLift Collagen Complex – firms and smooths for youthful elasticity

• Antioxidant C+E Ferulic Radiance Serum – brightens and defends against oxidative stress

• Needle-Free Wrinkle Smoother – softens fine lines without irritation

• Ultra Retinol 10x + Bakuchiol Serum – boosts cell turnover with gentle plant retinol

• Advanced Retinol Eye Repair – targets puffiness and under-eye wrinkles

• Cellular Repair Growth Factor Peptides Serum – rejuvenates and supports skin repair

• Advanced Neck Lift Firming Complex – improves tone and texture along the jawline and neck

• Even Tone Brightening Cream – evens discoloration for radiant, balanced skin

Dr Onyx Adegbola MD PhD

Track Smarter. Eat Better. Thrive. Download the GLP1 Support App now available in the Apple Store: https://apps.apple.com/us/app/glp1-support-by-dr-onyx-md-phd/id6759457103

The second big signal is that perimenopause is being recoded as a multisystem performance problem, not a hot-flash silo.
In Not Your Mother’s Menopause, Menopause Mastery, Hit Play Not Pause, and OvaryActive, pelvic pain, recurrent “UTIs,” brain fog, 2–4 a.m. awakenings, mood disruption, sexual dysfunction, and future cognitive risk all surface as clinically linked manifestations of estrogen-sensitive brain, bladder, bone, and vulvovaginal tissues rather than as isolated complaints.
The clinical implication is clear: structured intake, focused pelvic exams, earlier GSM treatment, sleep and cognition screening, and aggressive risk-factor management—especially hearing, lipids, and vascular health—will likely outperform symptom-by-symptom firefighting.

The third trend is commercial: menopause is no longer just a gynecology category but a midlife platform opportunity.
Hello Menopause frames workplace support as a productivity lever, The Plus SideZ links menopause care with obesity medicine and GLP-1 readiness, and The Skin Real plus The Girlfriend Doctor show how dermatology and integrative care are being pulled into the same orbit as patients look for symptom relief that also preserves function, identity, and appearance.
The winners will be the groups that turn this into infrastructure—evidence-based hormone protocols, GSM pathways, pelvic PT and sexual-health referrals, cardiometabolic and bone protection, brief follow-up workflows, and regulated products rather than compounded workarounds—because the market is moving from content and supplements toward longitudinal, integrated service delivery.

URL: Listen Here

This episode challenges prevailing misconceptions from the past two decades that equate menopausal hormones with higher breast cancer risk, highlighting WHI findings that estrogen-alone reduced both incidence and mortality. The guests review evidence on the safety of vaginal estrogen (including in many survivors), the cognitive and skeletal benefits of estrogen, the importance of route and timing to mitigate thrombotic risk, and the need for nuanced, patient-centered decision-making.

• The long-standing fear that menopausal hormone therapy (MHT) broadly increases breast cancer risk is overstated; in the WHI estrogen-alone arm (hysterectomized women), breast cancer incidence and mortality were reduced, and family history—even BRCA1 status after prophylactic oophorectomy—is not an absolute contraindication to appropriately selected MHT.

• Low-dose vaginal estrogen has minimal systemic absorption and is generally considered safe for most women, including many breast cancer survivors—especially those on tamoxifen—while caution and shared decision-making are advised for women on aromatase inhibitors.

• Estrogen supports brain health (cognition, mood, sleep) and bone integrity; it is highly effective at preventing fractures, though skeletal benefits wane after discontinuation—challenging the dogma of “lowest dose for the shortest time” in all patients.

• Thrombotic risk with MHT is small and route-dependent: oral estrogen modestly increases venous thromboembolism risk, whereas transdermal estrogen is associated with lower VTE risk; arterial events are a greater concern when initiating therapy later in life among women with atherosclerosis.

• Evidence appraisal should integrate a “mosaic” of high-quality observational and randomized data rather than rely on single studies; the initial media messaging around WHI contributed to confusion that still impedes patient care.

For appropriately selected women—particularly those without a uterus—estrogen therapy does not increase and may reduce breast cancer risk while conferring meaningful benefits for bone and brain health; decisions about systemic and vaginal hormone use should be individualized, with route and timing optimized and oncology collaboration for cancer survivors.

When initiating MHT in symptomatic peri/postmenopausal patients, consider transdermal 17β-estradiol (with an appropriate progestogen if the uterus is intact) to minimize VTE risk, and explicitly counsel that family history alone is not a contraindication; for breast cancer survivors needing vaginal estrogen, coordinate with oncology—especially if the patient is on an aromatase inhibitor.

URL: Listen Here

This episode explores pelvic and bladder pain with an emphasis on interstitial cystitis, its frequent misdiagnosis as recurrent UTIs, and the pivotal role of hypoestrogenism and hypoandrogenism in midlife genitourinary symptoms. The guests outline a practical diagnostic approach, a stepwise management algorithm (from diet and pelvic PT to instillations, Botox, and neuromodulation), and highlight advances in sexual anatomy education and patient-centered resources relevant to current clinical care.

• Interstitial cystitis/bladder pain syndrome (IC/BPS) is frequently misdiagnosed as recurrent UTIs; phenotyping reveals bladder‑centric IC, pelvic floor myofascial pain, and non–bladder-centric (neural/hormonal) subtypes, each requiring different management.

• Genitourinary syndrome of menopause (GSM) and other hypoestrogenic states (e.g., lactation) affect the urethra, bladder, and vulvar vestibule; local estrogen plus androgens (testosterone or intravaginal DHEA) can substantially reduce urgency, frequency, pain, and ‘UTI-like’ flares.

• Accurate diagnosis requires excluding infection with appropriate testing (culture ± PCR), a structured pelvic exam (Q‑tip vestibular mapping, urethral/bladder palpation, pelvic floor assessment), and consideration of endometriosis and neuropathic contributors; cystoscopy is standard in many countries.

• Treatment ladder includes reducing bladder irritants (acidic/caffeinated/spicy items), antacid neutralizers (calcium glycerophosphate or calcium carbonate/Tums), short-course phenazopyridine for pain, pelvic floor physical therapy and diaphragmatic breathing, bladder instillations (heparin/DMSO), intradetrusor botulinum toxin, and sacral neuromodulation for refractory cases.

• Reflexive antibiotic use for culture-negative ‘UTIs’ is common and harmful to gut/vaginal/urinary microbiomes; menopause-focused care models, patient education, and multidisciplinary teams (urogynecology, pelvic PT, sexual medicine) are critical.

In midlife women with recurrent ‘UTI’ symptoms or bladder pain, first consider GSM-related local hormone deficiency—often involving both estrogen and androgens at the vestibule, urethra, and bladder—because targeted local hormone therapy can resolve symptoms and prevent unnecessary antibiotics.

For women ≥40 with recurrent UTI-like symptoms and negative/inconsistent cultures, perform a structured pelvic exam (Q‑tip vestibular mapping, urethral/bladder and pelvic floor assessment), obtain urine culture ± PCR, review bladder irritants, start local vaginal estrogen and consider adding low‑dose topical testosterone or intravaginal DHEA, and refer to pelvic floor physical therapy before prescribing further antibiotics.

URL: Listen Here

This episode reviews a peer‑reviewed analysis showing that serum testing, not saliva or dried blood spot, is the most reliable modality for monitoring transdermal testosterone replacement therapy because it correlates with clinical outcomes. The guests also outline practical implications for progesterone and estradiol monitoring and describe how urine testing can complement serum by illuminating metabolism and stress physiology.

• For men using transdermal testosterone, serum testing—rather than saliva or dried blood spot—best correlates with clinical outcomes; the review found no evidence that salivary testosterone tracks clinical response.

• Saliva and dried blood spot often read supraphysiologic after creams/gels (even at low doses), which can drive erroneous dose reductions and subtherapeutic treatment, risking failure to improve bone density, muscle mass, metabolic health, and sexual function.

• Urine testing is a complementary tool—not a primary dosing tool—for TRT, helping evaluate androgen metabolism (DHT, aromatization to estradiol), estrogen phase I/methylation, and HPA-axis stress physiology.

• Topical progesterone produces very high salivary levels without reliable serum elevations and may not protect the endometrium; oral micronized progesterone (100–200 mg) or carefully monitored vaginal routes are preferred for endometrial protection when systemic estrogen is used.

• Estradiol creams/gels have rapid pharmacokinetics that can evade spot serum sampling; patches lend themselves better to serum monitoring, while urine LC–MS can capture integrated exposure over time.

When monitoring transdermal testosterone therapy, rely on serum (total ± free) to titrate dose, because it aligns with validated endpoints (e.g., sexual function, LH suppression, erythrocytosis, bone/muscle effects), whereas salivary and dried blood spot values are discordant and can mislead dosing.

Standardize TRT monitoring to serum: obtain a consistent post-application trough sample (e.g., ~24 hours after gel/cream) to titrate toward a clinically appropriate range while tracking symptoms and safety labs (e.g., hematocrit). Do not use salivary or dried blood spot values to set TRT dose; use urine testing selectively to assess aromatization, DHT production, estrogen metabolism, and HPA-axis contributors.

URL: Listen Here

This episode features menopause coach Sara Larson, who shares her difficult perimenopause journey and how it informed her coaching approach that prepares and guides women through care, focusing on individualized strategies rather than quick fixes. She emphasizes patient education, iterative MHT dosing when used, self-advocacy, and holistic support—including mental fitness and nature-based experiences—to navigate grief, identity shifts, and common challenges like weight change.

• Perimenopause can present with severe, multidomain symptoms (e.g., joint pain, anxiety/depression, cognitive changes) and is frequently dismissed; self-education and advocacy are critical.

• Menopause hormone therapy (MHT) may be transformative but often requires individualized initiation and iterative dose adjustments over time; concomitant progesterone is needed with systemic estrogen in women with a uterus, and clear patient education is essential.

• Structured preparation before brief clinic visits—symptom inventories, triggers, duration, and goals—improves communication, treatment selection, and adherence; post-visit follow-up clarifies instructions (e.g., proper use of vaginal estrogen).

• Many women experience grief and identity shifts alongside weight changes; reframing goals toward embodiment, self-compassion, and functional strength (often supported by mental fitness coaching and outdoor experiences) can be therapeutic.

• Letting go of “shoulds,” cultivating autonomy, and practicing self-advocacy are central to navigating menopause amid confusing public messaging; there is no one-size-fits-all path.

A simple, structured pre-visit process (patient-completed symptom checklist and priorities) combined with brief post-visit reinforcement markedly enhances the quality and efficiency of menopause care in time-limited clinical encounters.

Adopt a standardized menopause intake and after-visit protocol: have patients submit a 1-page symptom and goals ‘cheat sheet’ before the visit, and provide written, plain-language instructions afterward (including the need for progesterone with systemic estrogen when the uterus is present and how to use vaginal estrogen) with a brief follow-up call to confirm understanding and adherence.

URL: Listen Here

This episode outlines why menopause must be recognized as a workplace issue and how employers can act without major new spend by integrating existing benefits into ‘midlife care,’ training leaders in compassionate conversations, and ensuring affordable access to therapies. The discussion highlights the sizable economic burden of untreated symptoms and evidence that appropriate treatment can eliminate a wage penalty—underscoring the imperative for clinicians and employers to identify and manage menopause proactively.

• Menopause coincides with peak career years; symptoms like sleep disruption, anxiety, and cognitive changes often precede hot flashes and significantly impair productivity and earnings.

• Menopause remains largely invisible in employer data because ICD-10 coding fragments symptoms across conditions; organizing benefits around “midlife care” can make needs visible and navigable.

• A practical employer playbook is the 3-H framework: Healthcare (integrate existing benefits under midlife care), Health (train leaders in compassionate conversations), and HRT/Nonhormonal Therapy Access (ensure coverage and affordability).

• Structured dialogue frameworks (ask–confirm–clarify–act) and proactive check-ins reduce stigma; don’t wait for employees to disclose—normalize support and involve men in decision-making.

• There is a strong business and moral case to act now (“pay now or pay later”): U.S. productivity losses are substantial, total costs soar when healthcare is included, and timely treatment (e.g., HRT when appropriate) can erase a documented wage penalty.

Menopause is a multisystem life stage that often first presents with mood, sleep, and cognitive symptoms rather than vasomotor complaints; timely recognition and evidence-based treatment (including HRT when appropriate or nonhormonal options) can prevent clinically meaningful work impairment and a documented earnings penalty.

Routinely screen patients aged ~40–60 for menopause-related symptoms and work impact (sleep, vasomotor, mood/anxiety, cognition); when indicated, initiate or refer for guideline-concordant therapy (HRT or nonhormonal), address sleep and mental health, and offer a concise note with practical work accommodations (e.g., flexible hours, temperature control, remote/hybrid days).

URL: Listen Here

This episode examines why miscarriage often feels isolating, highlighting the cultural ‘silence–stigma–shame’ cycle and the gap between clinical management and lived experience. It offers practical guidance for compassionate communication, validation of diverse grief responses, and evidence-based strategies to manage anxiety and depression in future pregnancies, including the considered use of antidepressants.

• Miscarriage is common (about 1 in 4 pregnancies) yet often hidden, creating a cycle of silence → stigma → shame that intensifies isolation.

• Naming and validating the loss matters; grief responses vary widely, and even very early or chemical pregnancies are real losses that warrant support.

• Supportive communication avoids minimizing phrases (especially those starting with “at least…”); instead, offer presence, listening, remembrance, and gentle check-ins over time.

• Anxiety in subsequent pregnancies is expected; management includes psychotherapy (e.g., CBT, mindfulness), reassurance/monitoring visits, and, when needed, safe medications.

• Current evidence does not show a significant increase in miscarriage risk with antidepressants; untreated depression/anxiety can worsen the perinatal course and future pregnancy experience.

Clinicians should proactively normalize and assess psychological sequelae after pregnancy loss and during subsequent pregnancies, using non-minimizing, trauma-informed communication and offering evidence-based treatments (psychotherapy, mindfulness, and when indicated SSRIs) while clarifying that antidepressants are not known to significantly raise miscarriage risk.

Implement a standardized post-loss follow-up: screen for depression, anxiety, and PTSD; use validating language (e.g., “What if you did nothing wrong? I’m here to listen.”); provide perinatal mental health referrals/resources; and schedule proactive check-ins in early subsequent pregnancy, discussing psychotherapy and SSRIs when appropriate.

URL: Listen Here

This episode spotlights how gaps in women’s health research—especially in perimenopause—have led to under-recognition and under-treatment of a wide array of symptoms that extend far beyond hot flashes. Andrea Donsky’s large community surveys (with abstracts published in Menopause) document 103+ symptoms, a neurocognitive symptom predominance, and a strong stress–insomnia link via 2–4 a.m. awakenings, underscoring the need for holistic, earlier, and personalized care. Specific survey methods and full publication details were not provided in the episode, limiting appraisal of design and generalizability.

• Large-scale community surveys identified 103+ menopause-related symptoms, with women reporting an average of 31 symptoms concurrently; prior medical literature listed far fewer and is outdated.

• Nine of the top 10 most common symptoms are neurocognitive/mental health related; fatigue is #1, followed by brain fog and sleep disturbance.

• Sleep disruption commonly features 2–4 a.m. awakenings largely linked to stress and cortisol dysregulation; other contributors include nocturia and night sweats.

• Women are frequently dismissed in clinical encounters (≈40%) and are often funneled to antidepressants first; a multimodal toolbox (nutrition, lifestyle, supplements, and/or hormones) is advocated rather than a one-size-fits-all approach.

• Foundational care—balancing blood sugar, emphasizing fiber and quality fats (e.g., omega-3s), nurturing digestion, eating more plants, adequate hydration, stress management, and strength training—is essential; patients should not have to “earn” access to hormone therapy.

Perimenopause symptom burden is broad and predominantly neurocognitive (fatigue, brain fog, stress-related insomnia), so clinicians should screen beyond vasomotor complaints and address stress/cortisol dysregulation while offering individualized, multimodal treatment options (including hormone therapy when appropriate) rather than defaulting to antidepressants.

At visits with women aged 40–60 who report poor sleep or fatigue, add a brief perimenopause screen that specifically asks about 2–4 a.m. awakenings, daytime fatigue/brain fog, nocturia, and anxious rumination; initiate a structured sleep plan (cool, dark bedroom, no late meals/exercise, evening wind-down, consider magnesium glycinate) and evaluate for vasomotor symptoms and suitability for menopausal hormone therapy in parallel.

URL: Listen Here

Part 1 centers on a 65-year-old patient’s lived experience with GLP-1 therapy: rapid relief of ‘food noise,’ restored satiety, identity shifts, and greater capacity for self-care, while reframing obesity as a disease rather than a moral failing. The hosts discuss the effects of grief and perimenopause, emphasize slow, sustainable change and non-scale wins, and address access barriers, before introducing an obesity-medicine physician for deeper clinical context in Part 2. As a largely narrative episode with sponsor messages, few formal studies are cited.

• GLP-1/GIP-based anti-obesity medications can markedly reduce “food noise,” enhance satiety, and expand daily capacity, enabling sustainable behavior change—even for patients over 60.

• Obesity is framed as a chronic metabolic disease rather than a personal failing; shifting language from “weight loss” to “health gain” and using non-scale goals improves reframing and self-compassion.

• Life stressors such as grief and perimenopause/menopause can intensify hyperphagia and weight regain; some patients report benefit from evaluated hormone replacement therapy (HRT).

• Slow, steady weight reduction may lessen skin laxity and body dysmorphia; functional measures (fit of clothes, energy, participation in life) are valuable success metrics.

• Access barriers persist: many GLP-1 insurance denials are appealable and telehealth/advocacy services can help patients navigate coverage and affordability.

Treat obesity proactively as a chronic disease: in appropriately selected patients—including older adults—evidence-based anti-obesity pharmacotherapy (e.g., GLP-1 or GLP-1/GIP agents) can quiet pathologic hunger signals, enabling durable lifestyle change and meaningful improvements in quality of life and comorbidity control.

At the next visit with a patient struggling to sustain lifestyle changes, screen for persistent preoccupation with food (“food noise”) and poor satiety, discuss eligibility for GLP-1/GIP agents (e.g., semaglutide, tirzepatide), arrange close follow-up, and be prepared to support an insurance appeal within 90 days if initially denied.

URL: Listen Here

This episode bridges Ayurvedic and Western perspectives to tackle chronic inflammation, emphasizing circadian living, daily detox rituals, gut-centric nutrition, and personalized care based on doshas. It highlights menopause as a vata-phase transition and discusses turmeric/curcumin—augmented by piperine or fat—and synergistic herbs as practical tools to reduce systemic and neuroinflammation.

• Ayurveda frames inflammation as a core driver of symptoms and disease and offers practical, preventive tools: circadian alignment, gut-first nutrition, daily detox rituals, and stress modulation.

• Understanding an individual’s dosha (vata/air, pitta/fire, kapha/earth) guides personalization; the perimenopause-to-menopause transition reflects a pitta-to-vata shift (“vata syndrome”) marked by dryness, sleep disturbance, brain fog, and irregularity.

• Daily detox practices such as copper tongue scraping and oil pulling, plus periodic deeper cleanses, support oral/gut health and systemic inflammation; simple gut resets (e.g., kichari or bone broth) and a 12-hour overnight fast (e.g., 7 pm–7 am) are emphasized.

• Midlife nutrition should prioritize three structured meals with healthy fats and adequate protein to stabilize agni (digestive fire), hormones, and sleep; vegans may need strategic protein planning and supplementation.

• Turmeric/curcumin is highlighted as a pleiotropic anti-inflammatory with enhanced absorption when paired with black pepper (piperine) or fat; synergistic botanicals (e.g., boswellia, ginger, amla, guduchi) and adaptogenic teas (e.g., shatavari, tulsi, ashwagandha, brahmi) may support joint, metabolic, sleep, and neurocognitive health.

Reframing menopause as a pitta-to-vata circadian transition helps clinicians target the predominant vata features (dryness, insomnia, irregularity, brain fog) with grounding strategies—structured meals rich in healthy fats and adequate protein, sleep optimization, and gentle daily detox—to reduce inflammation and improve quality of life.

Initiate a 4-week trial for midlife patients of a daily anti-inflammatory routine: a 12-hour overnight fast (7 pm–7 am), three structured meals with added healthy fats, and a standardized curcumin supplement (e.g., 500–1000 mg curcuminoids/day co-administered with piperine or taken with a fat-containing meal), while adding morning copper tongue scraping and 1–2x/week oil pulling.

URL: Listen Here

This episode focuses on dementia prevention during perimenopause, synthesizing the 2024 Lancet Commission’s modifiable risk factors and emphasizing hearing-loss treatment and LDL-C control (including appropriate statin use) as high-yield levers. It clarifies that menopausal hormone therapy should not be used to prevent dementia, discusses the nuanced role of APOE4 testing, and advises against routine cognitive supplements except to correct documented deficiencies.

• The 2024 Lancet Standing Commission update identified 14 modifiable dementia risk factors accounting for ~45% of cases globally, adding untreated vision loss and high LDL cholesterol and shifting several risks (smoking, depression, inactivity, diabetes) into the midlife window.

• Hearing loss is the single largest modifiable risk factor; the 2023 ACHIEVE randomized trial showed that hearing-aid use plus audiologic counseling reduced cognitive decline by ~48% over three years in high-risk older adults.

• Elevated LDL cholesterol is a modifiable dementia risk; diet can help, but many patients will require pharmacotherapy—observational meta-analytic data suggest statins reduce dementia risk and do not harm cognition.

• APOE4 increases Alzheimer’s risk (with higher penetrance in women) but is non-deterministic; testing is optional, and clinicians should emphasize risk-factor control (LDL-C, blood pressure, diabetes, activity, sleep) regardless of genotype.

• Menopausal hormone therapy should not be initiated solely for dementia prevention; large reviews show no reduction (or increase) in dementia risk, though MHT remains appropriate for vasomotor and related symptom relief and for premature ovarian insufficiency.

Midlife is the pivotal window to reduce dementia risk—prioritize treatment of hearing loss and aggressive management of vascular risks (especially LDL-C) over unproven strategies such as using menopausal hormone therapy or general “brain” supplements.

Add hearing screening to midlife visits: ask about difficulty hearing conversations (especially in noise), refer for audiology if positive or suspected loss, and encourage early adoption of hearing aids to reduce cognitive decline risk.

URL: Listen Here

This episode debunks common myths that fibroids and endometriosis preclude the use of menopausal hormone therapy. Dr. Hirsch explains that low-dose, steady MHT is typically safe and effective in these patients when paired with progestogen, and that anticipated issues like irregular bleeding should be managed rather than used to deny therapy.

• A history of fibroids or endometriosis is not a contraindication to menopausal hormone therapy (MHT).

• Fibroids may increase the likelihood of irregular bleeding on MHT, but this alone should not preclude treatment; evaluate as appropriate while recognizing the bleeding may be fibroid-related.

• Low-dose, steady postmenopausal estrogen (e.g., transdermal) generally does not enlarge fibroids or reactivate endometriosis pain.

• Patients with fibroids or a history of endometriosis should receive combined estrogen-progestogen therapy; for endometriosis, include progestogen even after hysterectomy.

• MHT offers substantial symptom relief and potential long-term health benefits (e.g., bone and cardiovascular) when started appropriately, and care should be individualized rather than reflexively denying therapy.

For most women with fibroids or a history of endometriosis, appropriately dosed combined MHT (including progestogen even post-hysterectomy in endometriosis) can be used safely without typically provoking fibroid growth or endometriosis flares, and irregular bleeding alone should not be a reason to deny therapy.

Before initiating MHT in a patient with fibroids or prior endometriosis, document baseline pelvic status (e.g., transvaginal ultrasound for fibroids), start low-dose transdermal estrogen plus adequate progestogen (include progestogen even after hysterectomy for endometriosis), and arrange early follow-up to monitor and manage any bleeding or pain.

URL: Listen Here

This episode clarifies that topical estrogen rarely worsens melasma and that UV exposure is typically required alongside hormonal influence; systemic/oral estrogen poses a greater melasma risk than topical formulations. It also notes no evidence that topical estrogen exacerbates rosacea and suggests it may help as an adjunct in menopausal patients, emphasizing off-label use and shared decision-making.

• Melasma is a chronic, hormonally influenced condition that requires UV/visible light exposure to manifest; estrogen alone is typically insufficient to induce it.

• Current evidence does not robustly link topical or vaginal estrogen to melasma; reports are limited to isolated case reports and in vitro studies, whereas systemic/oral estrogen (e.g., OCPs) shows a stronger association.

• For patients with a history of melasma, topical estradiol can be trialed cautiously with a test spot and vigilant photoprotection, prioritizing sunscreens that include iron oxide to mitigate visible light.

• There are no known reports that topical estrogen worsens rosacea; rosacea may worsen with menopausal estrogen decline, so topical estrogen could be a helpful adjunct but is not a standalone treatment.

• Applying estrogen creams to facial skin is off-label; decisions should be individualized through shared decision-making with clinicians knowledgeable in midlife women’s health.

Topical estrogen is not an automatic contraindication in patients with a history of melasma; UV exposure is a key cofactor, and systemic estrogen carries a higher melasma risk than topical use based on current evidence.

If a patient with prior melasma wishes to try topical estradiol, initiate an 8–12 week test application on a low–sun-exposed area (e.g., neck or chest), enforce daily broad-spectrum photoprotection with an iron oxide–containing sunscreen, monitor closely for new or worsening hyperpigmentation, and discontinue/adjust if melasma develops.

URL: Listen Here

This episode reframes HRT for women in their 50s–70s by debunking WHI‑era myths, clarifying the timing hypothesis, and emphasizing safer regimens (especially transdermal estradiol and vaginal estrogen) to alleviate persistent symptoms. It highlights testosterone’s broader neurobehavioral and physical effects beyond libido and offers practical pathways for complex groups (migraine, clot history, breast cancer survivors) grounded in individualized risk–benefit and lifestyle measures. Some claims reference general or ongoing evidence without full bibliographic details provided in‑episode.

• It’s not too late for women in their 50s–70s to consider HRT: symptoms often persist and conditions like genitourinary syndrome of menopause (GSM) are progressive; decisions should be individualized rather than based on age cutoffs.

• The timing hypothesis supports greatest preventive benefit when HRT is started within 10 years of menopause, but this does not mean initiation is contraindicated later; formulation and route matter—transdermal estradiol and vaginal estrogen have favorable safety profiles versus oral synthetics.

• Cardiovascular disease and migraines are not absolute contraindications to HRT; assess and optimize cardiovascular risk factors routinely, and prefer transdermal estradiol plus micronized progesterone/testosterone as appropriate; family history of clots warrants evaluation rather than exclusion.

• Testosterone for women affects more than libido—many report improvements in motivation, mood, sleep, musculoskeletal discomfort, and vitality; onset varies, so start low and titrate slowly to minimize side effects (e.g., hair shedding from rapid changes).

• Breast cancer survivorship requires nuanced, individualized care: many can safely use vaginal estrogen; some use systemic hormones with specialist oversight; nonhormonal pillars—especially exercise and alcohol reduction—meaningfully impact symptoms and overall health.

For symptomatic women well beyond the 10‑year window after menopause, low‑dose transdermal estradiol and vaginal estrogen can be safe and effective when tailored to the individual—risks are driven more by formulation and route than by age alone, and cardiovascular disease is not a blanket contraindication.

In an older postmenopausal patient with persistent sleep disturbance, GSM, vasomotor or musculoskeletal symptoms, perform a focused CV/VTE risk review and offer a shared‑decision trial of low‑dose transdermal estradiol (e.g., 0.025 mg patch) plus local vaginal estrogen, avoiding oral synthetic estrogen/progestins; reinforce exercise and alcohol reduction at every visit.

URL: Listen Here

This episode explains how epithelial ovarian cancer is graded (microscopic aggressiveness/differentiation) and staged (extent of spread), outlines several grading schemes, and provides a simplified overview of FIGO staging. It emphasizes that most cases present as high-grade and stage III/IV due to late, nonspecific symptoms and lack of screening, highlighting the need for rapid specialist evaluation to guide treatment and prognosis.

• Epithelial ovarian cancer is typically detected late because symptoms are GI/GU and nonspecific, and there is no effective population screening; per the episode, about 80% are diagnosed at stage III or IV (Stage I: 5%, II: 15%, III: 50%, IV: 30%).

• Grade is a microscopic assessment of tumor cell behavior/aggressiveness (degree of differentiation) and is finalized by pathology after surgery.

• Multiple grading frameworks are described: level of aggression; degree of differentiation (well/moderately/poorly differentiated); macroscopic/imaging consistency (simple cyst → homogeneous/heterogeneous/solid); and malignant potential (benign/borderline/malignant). Increasing solidity/complexity correlates with higher malignant potential.

• Stage is the macroscopic extent of spread; simplified FIGO staging: I (ovary-confined), II (pelvis-confined), III (beyond pelvis), IV (distant metastasis).

• High-grade serous carcinoma predominates and, together with late-stage presentation, drives poor prognosis; higher grade and later stage predict worse survival.

Grade (microscopic differentiation/aggressiveness) and stage (macroscopic extent of spread) are distinct but jointly determine prognosis; because symptoms arise late and screening is ineffective, clinicians must maintain high suspicion for complex/solid adnexal masses and expedite surgical and pathologic evaluation to accurately define grade and stage.

For peri- or postmenopausal patients with a complex or solid adnexal mass on ultrasound or with persistent bloating, altered bowel/urinary habits, or pelvic pressure, promptly refer to a gynecologic oncologist for surgical evaluation and definitive staging rather than relying on screening tests.

Stay connected with Dr Onyx MD PhD for clinical insights and wellness tools that bridge science and everyday care:

Instagram ✦ X (Twitter) ✦ LinkedIn ✦ Website

Knowledge without execution changes nothing. The insights above only reach their full potential when integrated into a strategic, personalized plan. That’s where two offerings come in:

Healthcare complexity is overwhelming. Clinical studies, conflicting guidelines, and fragmented records leave most patients paralyzed.

Deploy your Dr Onyx MD PhD Medical AI Chatbot—a personalized architecture that synthesizes your medical history, the latest research, and your unique condition into clear, actionable insights.

It’s not a replacement for your doctors—it’s your secret weapon for making better decisions and becoming the CEO of your own care.

👉 Deploy your Medical AI Chatbot today and take control of your health narrative

Managing menopause isn’t about “getting through it”—it’s about doing it strategically. The Menopause Premium Program is a 16-week, high-touch protocol designed for high-performing women who demand more than quick fixes. With board-certified specialists, evidence-based hormone and non-hormonal options, and proactive risk reduction, this program helps restore clarity, stabilize sleep, and safeguard long-term health. If brain fog, disrupted nights, or unpredictable weight shifts are holding you back, this is your opportunity to take control with the same precision you bring to your career.

👉Discover the Menopause Premium Program